Immune parameters affecting adenoviral vector gene therapy in the brain

Reference

• Akli S., Caillaud C., Vigne E., Stratford-Perricaudet L. D., Poenaru L., Perricaudet M., Peschanski MR. Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genetics 1993; 3: 224–228
   PubMed Web of Science ®Google Scholar
• Armentano D., Sookdeo C. C., Hehir K. M., Gregory R. J., St George J. A., Prince G. A., Wadworth S. C., Smith AE. Charaterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995; 6: 1343–1353
   Google Scholar
• Bajocchi G., Feldman S. H., Crystal R. G., Mastrangeli A. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nature Genetics 1993; 3: 229–234
   PubMed Web of Science ®Google Scholar
• Bett A. J., Haddara W., Prevec L., Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802–8806
   PubMed Web of Science ®Google Scholar
• Byrnes A. P., Rusby J. E., Wood MJA, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995; 66: 1015–1024
   PubMed Web of Science ®Google Scholar
• Byrnes A. P., Wood MJA, Charlton HM. Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Therapy 1996; 3: 644–651
   PubMedGoogle Scholar
• Davidson B. L., Allen E. D., Kozarsky K. F., Wilson J. M., Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nature Genetics 1993; 3: 219–223
   PubMed Web of Science ®Google Scholar
• Dematteo R. P., Raper S. E., Ahn M., Fisher K. J., Burke C., Radu A., Widera G., Claytor B. R., Barker C. F., Markmann JF. Gene transfer to the thymus. A means of abrogating the immune response to recombinant adenovirus. Annals Surgery 1995; 222: 229–242
   PubMed Web of Science ®Google Scholar
• Dong Y., Wen P. Y., Manome Y., Parr M. J., Hirschowitz A., Chen L., Hirschowitz E., Crystal R. G., Kufe D. W., Fine HA. In vivo replication-deficient adenovirus vector mediated transduction of the cytosine deami-nase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996; 7: 713–720
   PubMed Web of Science ®Google Scholar
• Engelhardt J. F., Ye X., Doranz B., Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196–6200
   PubMed Web of Science ®Google Scholar
• Fabry Z., Raine C. S., Hart MS. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today 1994; 5: 566–571
   Google Scholar
• Graham F. L., Smilely J., Russel W. C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59–72
   PubMed Web of Science ®Google Scholar
• Guerette B., Vilquin J. T., Gingras M., Gravel C., Wook K. J., Tremblay JP. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLAIg. Hum Gene Ther 1996; 7: 1455–1463
   PubMed Web of Science ®Google Scholar
• Haecker S. E., Stedman H. H., Balice-Gordon R. J., Smith D. B., Greelish J. P., Mitchell M. A., Wells A., Sweeney H. L., Wilson JM. In vivo expression of full length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 1996; 7: 1907–1914
   PubMed Web of Science ®Google Scholar
• Hirschowitz E., Ohwada A., Pascal W. R., Russi T. J., Crystal RG. In vivo adenovirus-mediated gene transfer of the E. coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensi-tivity to 5-fluorocytosine. Hum Gene Ther 1995; 6: 1055–1063
   PubMed Web of Science ®Google Scholar
• Kajiwara K., Byrnes A. P., Charleton H. M., Wood MJA, Wood KJ. Immune responses to adenoviral vectors during gene transfer in the brain. Hum Gene Ther 1997; 8: 253–265
   PubMed Web of Science ®Google Scholar
• Kay M. A., Holterman A. X., Meuse L., Gown A., Ochs H. D., Linsley P. S., Wilson CB. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nature Genetics 1995; 11: 191–197
   PubMed Web of Science ®Google Scholar
• Kay M. A., Meuse L., Gown A. M., Linsley P., Hollenbaugh D., Aruffo A., Ochs H. D., Wilson CB. Transient immunosuppression with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686–4691
   PubMed Web of Science ®Google Scholar
• Khoury S. J., Akalin E., Chandraker A., Turka L. A., Linsley P. S., Sayegh M. H., Hancock WW. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Thl but spares Th2 cytokines in the central nervous system. J Immunology 1995; 155: 4521–4524
   PubMed Web of Science ®Google Scholar
• Kobayashi N., Allen N., Clendenon N. R., Ko LW. An improved rat brain-tumor model. J Neurosurg 1980; 53: 808–815
   PubMedGoogle Scholar
• Kochanek S., Clemens P. R., Mitani K., Chen H. H., Chan S., Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731–5736
   PubMed Web of Science ®Google Scholar
• Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Op Genetics Bevel 1993; 3: 499–503
   PubMed Web of Science ®Google Scholar
• Krougliak V., Graham FL. Development of cell lines capable of complementing E. l., E4 and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995; 6: 1575–1586
   PubMed Web of Science ®Google Scholar
• Lee M. G., Abina M. A., Haddada H., Perricaudet M. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 1995; 2: 256–262
   Google Scholar
• Mack C. A., Song W. R., Carpenter H., Wickham T. J., Kovesdi I., Harvey B. G., Magovern C. J., Isom O. W., Rosengart T., Falk-Pedersen E., Hackett N. R., Crystal R. G., Mastrangeli A. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Therapy 1997; 8: 99–109
   PubMed Web of Science ®Google Scholar
• Parks R. J., Chen L., Anton M., Sankar U., Rudnicki M. A., Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565–13570
   PubMed Web of Science ®Google Scholar
• Parks R. J., Wilson JM. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virology 1997; 71: 3293–3298
   PubMedGoogle Scholar
• Stratford-Perricaudet L. D., Levrero M., Chasse J. F., Perricaudet M., Briand P. Evaluation of the transfer and expression in mice of an enzyme encoding gene using a human adenovirus vector. Hum Gene Ther 1990; 1: 241–256
   PubMed Web of Science ®Google Scholar
• Tripathy S. K., Black H. B., Goldwasser E., Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Medicine 1996; 2: 545–550
   PubMed Web of Science ®Google Scholar
• Wilson C., Kay MA. Immunomodulation to enhance gene therapy. Nature Medicine 1995; 1: 887–889
   Google Scholar
• Wold WSM, Gooding LR. Region E3 of adenovirus: a cassette of genes involved in host immuno-surveillance and virus-cell interactions. Virology 1991; 184: 1–8
   PubMedGoogle Scholar
• Wood MJA, Charlton H. M., Wood K. J., Kajiwara K., Byrnes AP. Immune responses to adenovirus vectors in the nervous system. Trends Neuroscience 1996; 19: 497–501
   PubMed Web of Science ®Google Scholar
• Worgall S., Wolff G., Falck-Pedersen E., Crystal R. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37–44
   PubMed Web of Science ®Google Scholar
• Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gonczol E., Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994a; 91: 4407–4411
   PubMed Web of Science ®Google Scholar
• Yang Y., Nunes F. A., Berencsi K., Gonczol E., Engelhaxdt J. F., Wilson JM. Inactivation of E2a in recombinant adenovirus improves the prospect for gene therapy in cystic fibrosis. Nature Genetics 1994b; 7: 363–369
   Google Scholar
• Yang Y., Li Q., Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virology 1995a; 69: 2004–2015
   PubMed Web of Science ®Google Scholar
• Yang Y., Xiang Z., Ertl HCJ, Wilson JM. Upregulation of class I major histocompatibility complex antigens by interferon-γ is necessary for T-cell mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 1995b; 92: 7257–7261
   PubMed Web of Science ®Google Scholar
• Yang Y., Trinchieri G., Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Medicine 1995c; 1: 890–893
   PubMed Web of Science ®Google Scholar
• Yang Y., Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunology 1995; 155: 2564–2570
   PubMed Web of Science ®Google Scholar